SLC18A3 and cognition: Treatment with melatonin and N-acetyl-5-methoxytryptamine has been shown to inhibit the reduction of the levels of the proteins ChAT, VAchT, CHT1, and M1-mAchRs and improve the cognitive deficit in scopolamine-induced amnesia35.